Waldman Reid Alexander 4
4 · Veradermics, Inc · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Veradermics (MANE) CEO Waldman Reid Alexander Receives Equity Award
What Happened
Waldman Reid Alexander, CEO of Veradermics, received a derivative equity award on Feb 3, 2026 covering 556,399 shares at $0.00 (reported as an award/grant). On Feb 5, 2026 a small holding tied to Series A Convertible Preferred Stock was converted into common stock immediately prior to the company’s IPO (conversion entries show 1,437 shares converted). The award is recorded as a derivative security (not an open-market purchase or cash sale) and the reported per-share price for the award was $0.00.
Key Details
- Transaction dates: Award granted 2026-02-03; preferred conversion occurred 2026-02-05. Filing dated 2026-02-05 (covers period ending 2026-02-03).
- Prices/values: Award reported at $0.00 per share (total value shown as $0 in the filing). Conversion was automatic and involved no cash consideration.
- Shares owned after transaction: Not disclosed in the provided filing details.
- Footnotes of note:
- F1: Series A Convertible Preferred Stock automatically converted into common stock on a 10.067-for-1 basis immediately prior to the IPO, without further consideration.
- F2: The award vests 25% on Feb 3, 2027 (one-year cliff) and the remainder in equal monthly installments over the following 36 months, subject to continued service.
- Timeliness: The Form 4 was filed on Feb 5, 2026 for transactions around Feb 3–5, 2026 — no late filing flag was indicated.
Context
The 556,399-share item is a time‑vested equity award (derivative) rather than an open-market buy or sale; such grants are common for executives and reflect compensation rather than immediate market bets. The Feb 5 conversion was an automatic corporate conversion of preferred stock into common prior to the IPO and does not by itself indicate a purchase or sale by the insider.
Insider Transaction Report
- Conversion
Common Stock
[F1]2026-02-05+1,437→ 234,872 total - Conversion
Series A Convertible Preferred Stock
[F1]2026-02-05−1,437→ 0 total→ Common Stock (1,437 underlying) - Award
Stock Option (Right to Buy)
[F2]2026-02-03+556,399→ 556,399 totalExercise: $17.00Exp: 2036-02-03→ Common Stock (556,399 underlying)
Footnotes (2)
- [F1]On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]The option vests as to 25% of the underlying shares of Common Stock on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.